Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.08
DRRX's Cash-to-Debt is ranked higher than
51% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. DRRX: 2.08 )
Ranked among companies with meaningful Cash-to-Debt only.
DRRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 9.56 Max: No Debt
Current: 2.08
0.63
No Debt
Equity-to-Asset 0.46
DRRX's Equity-to-Asset is ranked lower than
70% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DRRX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
DRRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.04  Med: 0.44 Max: 0.96
Current: 0.46
-0.04
0.96
Debt-to-Equity 0.76
DRRX's Debt-to-Equity is ranked lower than
73% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. DRRX: 0.76 )
Ranked among companies with meaningful Debt-to-Equity only.
DRRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -10.82  Med: 0.87 Max: 6.74
Current: 0.76
-10.82
6.74
Debt-to-EBITDA -2.88
DRRX's Debt-to-EBITDA is ranked lower than
93% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. DRRX: -2.88 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DRRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.91  Med: -0.97 Max: -0.02
Current: -2.88
-23.91
-0.02
Piotroski F-Score: 4
Altman Z-Score: -8.04
Beneish M-Score: -1.68
WACC vs ROIC
15.60%
-433.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -23.66
DRRX's Operating Margin % is ranked lower than
69% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. DRRX: -23.66 )
Ranked among companies with meaningful Operating Margin % only.
DRRX' s Operating Margin % Range Over the Past 10 Years
Min: -230.76  Med: -108.14 Max: 30.25
Current: -23.66
-230.76
30.25
Net Margin % -28.39
DRRX's Net Margin % is ranked lower than
70% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. DRRX: -28.39 )
Ranked among companies with meaningful Net Margin % only.
DRRX' s Net Margin % Range Over the Past 10 Years
Min: -246.05  Med: -116.24 Max: 30.53
Current: -28.39
-246.05
30.53
ROE % -42.09
DRRX's ROE % is ranked lower than
69% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. DRRX: -42.09 )
Ranked among companies with meaningful ROE % only.
DRRX' s ROE % Range Over the Past 10 Years
Min: -297.22  Med: -100.4 Max: 81.39
Current: -42.09
-297.22
81.39
ROA % -17.18
DRRX's ROA % is ranked lower than
65% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. DRRX: -17.18 )
Ranked among companies with meaningful ROA % only.
DRRX' s ROA % Range Over the Past 10 Years
Min: -79.08  Med: -46.17 Max: 34.06
Current: -17.18
-79.08
34.06
ROC (Joel Greenblatt) % -528.63
DRRX's ROC (Joel Greenblatt) % is ranked higher than
97% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. DRRX: -528.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DRRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1371.98  Med: -742.02 Max: 500.45
Current: -528.63
-1371.98
500.45
3-Year Revenue Growth Rate 24.80
DRRX's 3-Year Revenue Growth Rate is ranked higher than
88% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. DRRX: 24.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DRRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.5  Med: 7.9 Max: 234
Current: 24.8
-35.5
234
3-Year EBITDA Growth Rate 67.90
DRRX's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. DRRX: 67.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DRRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.9 Max: 67.9
Current: 67.9
0
67.9
3-Year EPS without NRI Growth Rate 46.90
DRRX's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. DRRX: 46.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DRRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.15 Max: 46.9
Current: 46.9
0
46.9
GuruFocus has detected 3 Warning Signs with Durect Corp DRRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DRRX's 30-Y Financials

Financials (Next Earnings Date: 2019-03-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

DRRX Guru Trades in Q4 2017

First Eagle Investment 22,476,546 sh (+0.20%)
Jim Simons 681,400 sh (+590.37%)
Robert Bruce Sold Out
» More
Q1 2018

DRRX Guru Trades in Q1 2018

Joel Greenblatt 21,148 sh (New)
Jim Simons 1,764,600 sh (+158.97%)
First Eagle Investment 22,476,546 sh (unchged)
» More
Q2 2018

DRRX Guru Trades in Q2 2018

Jim Simons 3,269,494 sh (+85.28%)
First Eagle Investment 22,476,546 sh (unchged)
Joel Greenblatt Sold Out
» More
Q3 2018

DRRX Guru Trades in Q3 2018

Jim Simons 3,314,301 sh (+1.37%)
First Eagle Investment 22,476,546 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DRRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XKRX:214390, ASX:CAN, TSE:4517, TSXV:HIP, HKSE:00932, XKRX:006620, XKRX:000020, SZSE:300636, NAS:CPRX, ASX:AC8, NAS:PETQ, NAS:AQXP, XKRX:008490, XKLS:7081, BOM:532612, TPE:3705, TSE:4594, TSE:4597, SZSE:002817, XKRX:002250 » details
Traded in other countries:DC8.Germany,
Headquarter Location:USA
Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928.

Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928. Its pipeline products consist of DUR-928, RBP-7000, Posmir, Remoxy, Oradur, and others.

Ratios

vs
industry
vs
history
PB Ratio 4.72
DRRX's PB Ratio is ranked lower than
87% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. DRRX: 4.72 )
Ranked among companies with meaningful PB Ratio only.
DRRX' s PB Ratio Range Over the Past 10 Years
Min: 1.68  Med: 8.84 Max: 55.65
Current: 4.72
1.68
55.65
PS Ratio 3.37
DRRX's PS Ratio is ranked lower than
63% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DRRX: 3.37 )
Ranked among companies with meaningful PS Ratio only.
DRRX' s PS Ratio Range Over the Past 10 Years
Min: 0.91  Med: 8.22 Max: 20.84
Current: 3.37
0.91
20.84
EV-to-EBIT -14.17
DRRX's EV-to-EBIT is ranked lower than
97% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. DRRX: -14.17 )
Ranked among companies with meaningful EV-to-EBIT only.
DRRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -248  Med: -6.5 Max: 215.4
Current: -14.17
-248
215.4
EV-to-EBITDA -14.84
DRRX's EV-to-EBITDA is ranked lower than
96% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. DRRX: -14.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
DRRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -357.5  Med: -6.8 Max: 168.2
Current: -14.84
-357.5
168.2
EV-to-Revenue 2.99
DRRX's EV-to-Revenue is ranked lower than
59% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. DRRX: 2.99 )
Ranked among companies with meaningful EV-to-Revenue only.
DRRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.6  Med: 7.1 Max: 20.6
Current: 2.99
0.6
20.6
Current Ratio 2.72
DRRX's Current Ratio is ranked higher than
67% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. DRRX: 2.72 )
Ranked among companies with meaningful Current Ratio only.
DRRX' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 5.39 Max: 29.59
Current: 2.72
1.13
29.59
Quick Ratio 2.53
DRRX's Quick Ratio is ranked higher than
70% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. DRRX: 2.53 )
Ranked among companies with meaningful Quick Ratio only.
DRRX' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 4.82 Max: 28.73
Current: 2.53
1
28.73
Days Inventory 281.58
DRRX's Days Inventory is ranked lower than
78% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. DRRX: 281.58 )
Ranked among companies with meaningful Days Inventory only.
DRRX' s Days Inventory Range Over the Past 10 Years
Min: 191.08  Med: 250.47 Max: 353.27
Current: 281.58
191.08
353.27
Days Sales Outstanding 17.00
DRRX's Days Sales Outstanding is ranked higher than
96% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. DRRX: 17.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.9  Med: 38.75 Max: 55.94
Current: 17
14.9
55.94
Days Payable 99.38
DRRX's Days Payable is ranked lower than
69% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. DRRX: 99.38 )
Ranked among companies with meaningful Days Payable only.
DRRX' s Days Payable Range Over the Past 10 Years
Min: 55.54  Med: 91.22 Max: 143.93
Current: 99.38
55.54
143.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.90
DRRX's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. DRRX: -9.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DRRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.5  Med: -8 Max: -2.1
Current: -9.9
-28.5
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.86
DRRX's Price-to-Net-Cash is ranked lower than
59% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. DRRX: 10.86 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DRRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.33  Med: 18.55 Max: 525
Current: 10.86
2.33
525
Price-to-Net-Current-Asset-Value 6.91
DRRX's Price-to-Net-Current-Asset-Value is ranked lower than
68% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. DRRX: 6.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DRRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.03  Med: 12.06 Max: 176
Current: 6.91
2.03
176
Price-to-Tangible-Book 6.33
DRRX's Price-to-Tangible-Book is ranked lower than
87% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. DRRX: 6.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DRRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.37  Med: 9.02 Max: 184.55
Current: 6.33
1.37
184.55
Price-to-Median-PS-Value 0.41
DRRX's Price-to-Median-PS-Value is ranked higher than
82% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. DRRX: 0.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DRRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 1.25 Max: 14.63
Current: 0.41
0.13
14.63
Earnings Yield (Greenblatt) % -7.06
DRRX's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. DRRX: -7.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DRRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -52.2  Med: -13.7 Max: 48.9
Current: -7.06
-52.2
48.9

More Statistics

Revenue (TTM) (Mil) $34.48
EPS (TTM) $ -0.06
Beta2.21
Volatility91.64%
52-Week Range $0.74 - 2.55
Shares Outstanding (Mil)162.06

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 19 16 16
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.16 -0.23 -0.21
EPS without NRI ($) -0.16 -0.23 -0.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}